ストックスクリーナーアプリを入手
2.60
1.96%
0.05
アフターアワーズ：
2.61
0.010
+0.38%
Annexon Inc (ANNX) 最新ニュース
Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Millennium Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Transcript : Annexon, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
BNP Paribas Financial Markets Makes New $59,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
ProShare Advisors LLC Buys 14,475 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Jane Street Group LLC - Defense World
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference | ANNX Stock News - GuruFocus
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Nuveen Asset Management LLC Acquires 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Ameriprise Financial Inc. - Defense World
Deutsche Bank AG Acquires 28,448 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Northern Trust Corp - Defense World
Annexon reports promising Guillain-Barré treatment results By Investing.com - Investing.com India
Annexon (ANNX) Highlights Promising Results from Tanruprubart Ph - GuruFocus
Annexon reports promising Guillain-Barré treatment results - Investing.com Australia
Annexon Showcases Tanruprubart Data Demonstrating Improved Clini - GuruFocus
Annexon Showcases Tanruprubart Data Demonstrating Improved - GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - The Manila Times
New GBS Drug Shows 3X Better Outcomes Than Standard Care in Clinical Trial | ANNX Stock News - Stock Titan
Annexon Inc (NASDAQ: ANNX) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon (ANNX) Advances with Promising Neurological and Vision T - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Positi - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Position | ANNX Stock News - GuruFocus
Annexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic Diseases - Nasdaq
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
Hsbc Holdings PLC Has $156,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Dimensional Fund Advisors LP Buys 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon Announces Presentations on the Clinical Advancement - GlobeNewswire
Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday - Defense World
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - The Manila Times
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting | ANNX Stock News - GuruFocus
Annexon, Inc. Reports Improved Outcomes for Tanruprubart in Guillain-Barré Syndrome at 2025 Peripheral Nerve Society Annual Meeting - Nasdaq
Annexon Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):